Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.60
+0.89007.60%
Post-market: 12.57-0.0300-0.24%18:45 EDT
Volume:13.97M
Turnover:172.63M
Market Cap:1.76B
PE:-3.77
High:12.64
Open:11.90
Low:11.76
Close:11.71
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:2.11
T/O Rate:10.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.42
PE(LYR):-3.31

Loading ...

Intellia Therapeutics Inc - Public Offering Price Set at $10.75 per Share

THOMSON REUTERS
·
Apr 29

Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing

Simply Wall St.
·
Apr 29

Stock Track | Intellia Therapeutics Soars 5.06% Intraday on Multiple Analyst Upgrades and ARK Invest Buying

Stock Track
·
Apr 28

Chardan Lifts Price Target on Intellia Therapeutics to $30 From $27, Keeps Buy Rating

MT Newswires Live
·
Apr 28

Intellia Therapeutics price target raised to $30 from $28 at Citizens

TIPRANKS
·
Apr 28

Intellia Therapeutics Inc : Canaccord Genuity Raises Target Price to $58 From $48

THOMSON REUTERS
·
Apr 28

Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)

TIPRANKS
·
Apr 28

Intellia Therapeutics Inc : Leerink Partners Raises Target Price to $35 From $29

THOMSON REUTERS
·
Apr 28

Stock Track | Intellia Therapeutics Plunges 5.06% Following $150 Million Common Stock Offering Announcement

Stock Track
·
Apr 28

Intellia Therapeutics Launches $150 Million Stock Offering

MT Newswires Live
·
Apr 28

Stock Track | Intellia Therapeutics Plummets 8.58% Intraday on $150 Million Public Offering Announcement

Stock Track
·
Apr 28

Intellia Therapeutics Inc - Commences $150 Mln Underwritten Public Offering of Common Stock

THOMSON REUTERS
·
Apr 28

Press Release: Intellia Announces Proposed Public Offering of Common Stock

Dow Jones
·
Apr 28

Intellia Therapeutics Is Maintained at Neutral by Baird

Dow Jones
·
Apr 28

Intellia Therapeutics price target raised to $15 from $11 at Morgan Stanley

TIPRANKS
·
Apr 28

Intellia Therapeutics price target raised to $13 from $7 at Baird

TIPRANKS
·
Apr 28

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Biogen (BIIB)

TIPRANKS
·
Apr 27

Intellia Therapeutics Shares Jump 8% Premarket After Rare Genetic Disorder Therapy Meets Main Goal in Trial

THOMSON REUTERS
·
Apr 27

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Reuters
·
Apr 27

Intellia starts rolling FDA BLA submission for lonvo-z in hereditary angioedema

Reuters
·
Apr 27